Resources from the same session
118O - Definitive results for NSCLC and Bladder cancer cohorts in the phase 2a trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)
Presenter: Ignacio Melero
Session: Proffered Paper session 1
Resources:
Abstract
LBA2 - First-line (1L) durvalumab plus platinum-etoposide for patients with extensive-stage SCLC (ES-SCLC): Primary results from the Phase 3b LUMINANCE study
Presenter: Niels Reinmuth
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
LBA3 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC: 5-year overall survival (OS) update from the POSEIDON study
Presenter: Solange Peters
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 118O, LBA2 and LBA 3
Presenter: Rolf Stahel
Session: Proffered Paper session 1
Resources:
Slides
Webcast
64O - Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic nonsquamous non-small cell lung cancer (NSCLC): phase 3 LEAP-006 study
Presenter: Roy S. Herbst
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
65O - Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy
Presenter: Natasha Leighl
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1
Resources:
Webcast